Brief Title
Intravitreal Injections of Melphalan for Retinoblastoma
Official Title
Intravitreal Injections of Melphalan for Retinoblastoma
Brief Summary
Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials. Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan. In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.
Detailed Description
Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or with vitreal seeding of the disease.
Study Type
Interventional
Primary Outcome
treatment response
Secondary Outcome
complications
Condition
Retinoblastoma
Intervention
IVit Melphalan
Study Arms / Comparison Groups
IVit Treatment group
Description: Intravitreal injections of Melphalan
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
10
Start Date
March 2012
Completion Date
August 2015
Primary Completion Date
August 2015
Eligibility Criteria
Inclusion Criteria: - Retinoblastoma that has not responded to chemotherapy - Retinoblastoma that has vitreal seeding Exclusion Criteria: - previous failure of IVit Melphalan
Gender
All
Ages
N/A - 20 Years
Accepts Healthy Volunteers
No
Contacts
Shahar Frenkel, MD, PhD, ,
Location Countries
Israel
Location Countries
Israel
Administrative Informations
NCT ID
NCT01558960
Organization ID
RB-001-HMO-CTIL
Responsible Party
Sponsor
Study Sponsor
Hadassah Medical Organization
Study Sponsor
Shahar Frenkel, MD, PhD, Principal Investigator, Hadassah Medical Organization
Verification Date
March 2012